GH Research (GHRS) Cash from Investing Activities (2021 - 2025)
GH Research's (GHRS) quarterly Cash from Investing Activities came in at $8.8 million in Q4 2025, down 58.56% year-on-year from $21.3 million in Q4 2024, and down 9.65% quarter-over-quarter from $9.8 million in Q3 2025.
GH Research (GHRS) Cash from Investing Activities (2021 - 2025) Analysis & Trends
GH Research's Cash from Investing Activities history runs 5 years deep, the most recent figure standing at $8.8 million for Q4 2025.
- On a quarterly basis, Cash from Investing Activities fell 58.56% year-over-year to $8.8 million in Q4 2025; TTM through Dec 2025 was $46.2 million, a 29.11% decrease from a year earlier, with the FY2025 full-year figure at $46.2 million, down 29.11% from the prior year.
- Cash from Investing Activities eased to $8.8 million in Q4 2025 per GHRS's latest filing, from $9.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $21.3 million in Q4 2024 and bottomed at -$84.6 million in Q4 2022.
- The 5-year median for Cash from Investing Activities is -$12000.0 (2021), against an average of -$1.4 million.
- Across the five-year window, Cash from Investing Activities tumbled 540120.0% in 2023 and soared 191150.0% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at -$19000.0 in 2021, then plunged by 445368.42% to -$84.6 million in 2022, then jumped by 99.97% to -$24000.0 in 2023, then jumped by 88979.17% to $21.3 million in 2024, then slumped by 58.56% to $8.8 million in 2025.
- Per Business Quant, the three latest GHRS Cash from Investing Activities figures stand at $8.8 million (Q4 2025), $9.8 million (Q3 2025), and $15.7 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 172.62 Mn |
| 10 | GH Research | 1.65 Bn | 1.65 Bn | - | 8.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.84 Mn |
| Dec 31, 2025 | 8.84 Mn |
| Sep 30, 2025 | 9.78 Mn |
| Sep 30, 2025 | 9.78 Mn |
| Jun 30, 2025 | 15.71 Mn |
| Jun 30, 2025 | 15.71 Mn |
| Mar 31, 2025 | 11.84 Mn |
| Mar 31, 2025 | 11.84 Mn |
| Dec 31, 2024 | 21.33 Mn |
| Dec 31, 2024 | 21.33 Mn |
| Sep 30, 2024 | 15.28 Mn |
| Sep 30, 2024 | 15.28 Mn |
| Jun 30, 2024 | 19.73 Mn |
| Jun 30, 2024 | 19.73 Mn |
| Mar 31, 2024 | 8.79 Mn |
| Mar 31, 2024 | 8.79 Mn |
| Dec 31, 2023 | -24,000.00 |
| Dec 31, 2023 | -24,000.00 |
| Sep 30, 2023 | -8,000.00 |
| Sep 30, 2023 | -8,000.00 |